ProfileGDS4814 / ILMN_1766275
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 71% 69% 70% 73% 72% 70% 68% 72% 70% 66% 73% 70% 72% 71% 71% 74% 71% 71% 70% 70% 70% 70% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)78.239271
GSM780708Untreated after 4 days (C2_1)68.961269
GSM780709Untreated after 4 days (C3_1)74.692870
GSM780719Untreated after 4 days (C1_2)84.592273
GSM780720Untreated after 4 days (C2_2)80.154272
GSM780721Untreated after 4 days (C3_2)74.468670
GSM780710Trastuzumab treated after 4 days (T1_1)66.331168
GSM780711Trastuzumab treated after 4 days (T2_1)79.274972
GSM780712Trastuzumab treated after 4 days (T3_1)72.792370
GSM780722Trastuzumab treated after 4 days (T1_2)63.293966
GSM780723Trastuzumab treated after 4 days (T2_2)86.01173
GSM780724Trastuzumab treated after 4 days (T3_2)74.423270
GSM780713Pertuzumab treated after 4 days (P1_1)83.400472
GSM780714Pertuzumab treated after 4 days (P2_1)78.720871
GSM780715Pertuzumab treated after 4 days (P3_1)77.088471
GSM780725Pertuzumab treated after 4 days (P1_2)93.274874
GSM780726Pertuzumab treated after 4 days (P2_2)77.730271
GSM780727Pertuzumab treated after 4 days (P3_2)77.824771
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)72.11470
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)73.611970
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)74.238470
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)73.115670
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)82.535172